139 related articles for article (PubMed ID: 12900780)
21. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
23. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
24. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
25. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.
Lee KH; Lee JH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Seo EJ; Park CJ; Chi HS; Lee JS
Bone Marrow Transplant; 2003 Oct; 32(8):835-42. PubMed ID: 14520431
[TBL] [Abstract][Full Text] [Related]
27. Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse.
Wiesneth M; Schreiner T; Bunjes D; Bischof C; Erne E; Maccari B; Kubanek B
J Hematother; 1999 Jun; 8(3):269-74. PubMed ID: 10417050
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
[TBL] [Abstract][Full Text] [Related]
30. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
31. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
32. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Hassan M
Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
[TBL] [Abstract][Full Text] [Related]
33. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children.
Bader P; Hölle W; Klingebiel T; Handgretinger R; Benda N; Schlegel PG; Niethammer D; Beck J
Bone Marrow Transplant; 1997 Apr; 19(7):697-702. PubMed ID: 9156247
[TBL] [Abstract][Full Text] [Related]
34. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.
Suttorp M; Schmitz N; Dreger P; Schaub J; Löffler H
Leukemia; 1993 May; 7(5):679-87. PubMed ID: 8097800
[TBL] [Abstract][Full Text] [Related]
36. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats.
Frankel W; Chan A; Corringham RE; Shepherd S; Rearden A; Wang-Rodriguez J
Am J Hematol; 1996 Aug; 52(4):281-7. PubMed ID: 8701946
[TBL] [Abstract][Full Text] [Related]
37. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
[TBL] [Abstract][Full Text] [Related]
38. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
39. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
40. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia.
Ramírez M; Díaz MA; García-Sánchez F; Velasco M; Casado F; Villa M; Vicario JL; Madero L
Bone Marrow Transplant; 1996 Dec; 18(6):1161-5. PubMed ID: 8971389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
